18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:March 1, 2016
End Date:June 5, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Reproducibility of 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

In the current study, the investigators plan to expand the knowledge of Positron Emission
Tomography/Magnetic Resonance (PET/MR) reliability by assessing the repeatability of
fludeoxyglucose (FDG) standardized uptake values (SUV) measurements, as well as apparent
diffusion coefficients (ADC) measurements, in a broad population of patients with malignant
solid tumors.


Inclusion Criteria:

- Patients with histologically confirmed malignant solid tumors (local or metastatic,
newly diagnosed or recurrent disease).

- Patient must have at least one lesion measuring ≥ 2.0 cm.

- 18 years of age or older.

- Ability to provide informed consent.

Exclusion Criteria:

- Cancer therapy within 30 days of baseline imaging.

- Uncontrolled intercurrent illness including, but not limited to active infections.

- Patients with insulin-dependent diabetes.

- Patients with metal devices in the body including, but not limited to metallic joint
prostheses, artificial heart valves, pacemakers, and cochlear implants.

- Patients who are pregnant or nursing.

- Inability to tolerate 60 minutes of PET imaging.

- Inability to comply with study procedures.
We found this trial at
1
site
Washington University School of Medicine
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Richard L Wahl, M.D.
Phone: 314-362-7100
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials